Involvement of TRPV1 and the efficacy of α-spinasterol on experimental fibromyalgia symptoms in mice

Publication date: Available online 8 January 2020Source: Neurochemistry InternationalAuthor(s): Susana Paula Moreira Fischer, Indiara Brusco, Evelyne da Silva Brum, Maria Fernanda Pessano Fialho, Camila Camponogara, Rahisa Scussel, Ricardo Andrez Machado-de-Ávila, Gabriela Trevisan, Sara Marchesan OliveiraAbstractFibromyalgia is characterised mainly by symptoms of chronic widespread pain and comorbidities like depression. Although these symptoms cause a notable impact on the patient's quality of life, the underlying aetiology and pathophysiology of this disease remain incompletely elucidated. The transient receptor potential vanilloid type 1 (TRPV1) is a polymodal receptor that is involved in the development of nociceptive and depressive behaviours, while α-spinasterol, a multitarget TRPV1 antagonist and cyclooxygenase inhibitor, presents antinociceptive and antidepressant effects. The present study investigated the involvement of the TRPV1 channel and the possible effects of α-spinasterol on nociceptive and depressive-like behaviours in an experimental fibromyalgia model. The fibromyalgia model was induced with a subcutaneous (s.c.) injection of reserpine (1 mg/kg) once daily for 3 consecutive days in male Swiss mice. Reserpine administration depleted monoamines and caused mechanical allodynia. This dysfunction was inhibited by SB-366791 (1 mg/kg, oral route [p.o.]), a selective TRPV1 antagonist, with a maximum inhibition (Imax) of 73.4 ± 15.5%, or by the single ...
Source: Neurochemistry International - Category: Neuroscience Source Type: research